FORT WORTH, TX, Jan. 03, 2024 (GLOBE NEWSWIRE) — Sanara MedTech Inc. announced today its exclusive license agreement with Tufts University to develop and commercialize patented collagen peptides. The agreement covers 18 unique collagen peptides and marks a significant milestone for Sanara as it seeks to expand its bioactive collagen peptide-based product line and improve patient care while reducing healthcare costs.
Zach Fleming, the CEO of Sanara MedTech Inc., expressed his excitement about the licensing agreement, stating, Sanara has established itself as a leader in bioactive collagen peptides with CellerateRX Surgical Powder. We see significant opportunities to broaden our existing product line and develop new applications that can help improve outcomes and advance patient care. The technology we have licensed from Tufts, supported by our research and development team at Rochal, will play a crucial role in expanding our collagen product offerings.
Sanara MedTech Inc. is a Fort Worth-based medical technology company that focuses on developing transformative technologies for the surgical, chronic wound, and skincare markets. The company markets, distributes, and develops surgical, wound, and skincare products for use in hospitals, clinics, and all post-acute care settings. Sanara also offers wound care and dermatology virtual consultation services through telemedicine.
Sanara’s product portfolio includes CellerateRX Surgical Activated Collagen, FORTIFY TRG Tissue Repair Graft, and FORTIFY FLOWABLE Extracellular Matrix, along with a range of advanced biologic products concentrating on bone matrix, amniotic membrane allograft, and surgical solutions. In the wound care market, Sanara provides BIAKÅS Antimicrobial Skin and Wound Cleanser, BIAKÅS Antimicrobial Wound Gel, BIAKÅS Antimicrobial Skin and Wound Irrigation Solution, and HYCOL Hydrolyzed Collagen. The company’s pipeline also includes promising product candidates focusing on mitigating opportunistic pathogens and biofilm, wound recovery, tissue debridement, and cell-compatible substrates.
The exclusive license agreement with Tufts University represents a significant step forward for Sanara, enabling the company to leverage cutting-edge collagen peptide technology. By combining Tufts’ expertise with Sanara’s research and development capabilities, the company aims to advance its product offerings and expand within the surgical, wound care, and skincare markets.
As with any forward-looking statement, various risks and uncertainties may affect the actual outcomes and results. The statements made in this press release are subject to change based on factors such as product demand, market acceptance, economic conditions, competition, pricing, regulatory approval process, and integrations of any acquisitions. The company remains committed to meeting quality and regulatory requirements while pursuing strategic partnerships to drive innovation and improve patient outcomes.
Sanara MedTech Inc. continues to prioritize its mission of enhancing clinical outcomes and reducing healthcare expenditures. With a focus on delivering transformative technologies and expanding its product offerings, the company remains at the forefront of the medical technology industry.
As Sanara MedTech Inc. embarks on this new venture through its exclusive license agreement with Tufts University, the future holds immense potential for the development of innovative collagen peptide-based applications that can revolutionize patient care.
